Gabaergic Neurons In Neurodegeneration plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
GABAergic neurons are inhibitory neurons that utilize gamma-aminobutyric acid (GABA) as their primary neurotransmitter. They play crucial roles in maintaining neural circuit balance, preventing hyperexcitability, and coordinating information processing throughout the brain. Dysfunction of GABAergic neurons contributes significantly to hyperexcitability, seizures, and network dysfunction observed in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis[1].
GABAergic interneurons in the cortex and hippocampus are remarkably diverse[2]:
| Type | Target | Marker | Function |
|---|---|---|---|
| PV basket cells | Pyramidal soma | Parvalbumin | Fast, powerful inhibition |
| CCK basket cells | Pyramidal soma | CCK, CB1 | Modulated inhibition |
| Axo-axonic cells | Axon initial segment | Parvalbumin | Output control |
| Type | Target | Marker | Function |
|---|---|---|---|
| SST interneurons | Dendrites | Somatostatin | Dendritic inhibition |
| VIP interneurons | Dendrites | VIP | Disinhibition |
| Neurogliaform cells | Distal dendrites | NPY | Volume transmission |
GABAergic neurotransmission depends on specific machinery[3]:
Ligand-gated chloride channels with multiple subunits:
| Subunit | Location | Function |
|---|---|---|
| α1 | Widely distributed | Sedation |
| α2 | Anxiety, motor | Anxiolysis |
| α3 | Sparse | Muscle tone |
| α5 | Hippocampus | Memory |
Metabotropic receptors:
GABAergic dysfunction in AD is extensive[4]:
Amyloid-beta effects:
Tau pathology:
Network dysfunction:
| Approach | Target | Status |
|---|---|---|
| GABA-A modulators | Cl- channel | Approved |
| GABA-B agonists | GPCR | Research |
| Neurosteroids | Allosteric sites | Clinical trials |
GABAergic changes in PD are central to motor dysfunction[5]:
GABAergic loss is early and progressive[6]:
Cortical hyperexcitability features prominently[7]:
| Drug Class | Example | Mechanism | Indication |
|---|---|---|---|
| Benzodiazepines | Diazepam | Positive allosteric modulators | Anxiety, sedation |
| Barbiturates | Phenobarbital | Direct activation | Seizures |
| Neurosteroids | Allopregnanolone | δ subunit modulation | Depression |
Palop JJ, Mucke L. Epilepsy and hyperexcitability in Alzheimer's disease. Nat Rev Neurosci. 2010
Zhou X, et al. GABAergic dysfunction in Alzheimer's disease. J Alzheimers Dis. 2022
Turner MR, et al. Cortical hyperexcitability in ALS. Lancet Neurol. 2018
Gabaergic Neurons In Neurodegeneration plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Gabaergic Neurons In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Palop JJ, Mucke L. (2010). Epilepsy and hyperexcitability in Alzheimer's disease. Nature Reviews Neuroscience, 11(12), 837-847. https://doi.org/10.1038/nrn2930 ↩︎
Freund TF, Katona I. (2007). Perisomatic inhibition. Neuron, 56(1), 33-42. https://doi.org/10.1016/j.neuron.2007.09.012 ↩︎
Benarroch EE. (2007). GABA receptor heterogeneity, function, and implications for CNS disorders. Neurology, 68(8), 612-622. ↩︎
Zhou X, et al. (2022). GABAergic dysfunction in Alzheimer's disease: From molecular mechanisms to therapeutic opportunities. Journal of Alzheimer's Disease, 86(2), 575-596. ↩︎
Albin RL, et al. (2002). The basal ganglia and disorders of movement: Pathophysiology and treatment strategies. In: The Basal Ganglia VII. Springer. ↩︎
Albin RL, et al. (2020). Early GABAergic dysfunction in prodromal Huntington's disease. Brain, 143(5), e40. ↩︎
Turner MR, et al. (2018). Cortical hyperexcitability in ALS: Diagnostic and therapeutic implications. Lancet Neurology, 17(4), 330-342. ↩︎